The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients.

ABSTRACT:

Background

Oral tacrolimus therapy is effective for refractory ulcerative colitis (UC), but dose adjustment according to the trough concentrations which varies largely among individuals, is required. This study aimed to identify factors to predict the tacrolimus dose required for achieving the target trough level for remission induction of UC.

Methods

Forty-seven consecutive UC patients who were treated with tacrolimus were retrospectively analyzed. Tacrolimus doses were adjusted every 2 or 3 days to achieve trough concentrations of 10-15 ng/mL. The dose required for reaching the target trough level was analyzed based on disease characteristics, course of trough concentrations, and gene polymorphism related to tacrolimus metabolism.

Results

Median daily dose of tacrol

SUBMITTER: Hiraoka S 

PROVIDER: S-EPMC4450494 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature